Use of adeno-associated virus-mediated delivery of mutant huntingtin to study the spreading capacity of the protein in mice and non-human primates.


Journal

Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169

Informations de publication

Date de publication:
07 2020
Historique:
received: 09 12 2019
revised: 20 03 2020
accepted: 16 05 2020
pubmed: 23 5 2020
medline: 15 7 2021
entrez: 23 5 2020
Statut: ppublish

Résumé

In order to model various aspects of Huntington's disease (HD) pathology, in particular protein spread, we administered adeno-associated virus (AAV) expressing green fluorescent protein (GFP) or GFP coupled to HTT-Exon1 (19Q or 103Q) to the central nervous system of adult wild-type (WT) mice and non-human primates. All animals underwent behavioral testing and post-mortem analyses to determine the long-term consequences of AAV injection. Both mice and non-human primates demonstrated behavioral changes at 2-3 weeks post-surgery. In mice, these changes were absent after 3 months while in non-human primates, they persisted in the majority of tested animals. Post-mortem analysis revealed that spreading of the aggregates was limited, although the virus did spread between synaptically-connected brain regions. Despite circumscribed spreading, the presence of mHTT generated changes in endogenous huntingtin (HTT) levels in both models. Together, these results suggest that viral expression of mHTTExon1 can induce spreading and seeding of HTT in both mice and non-human primates.

Identifiants

pubmed: 32439599
pii: S0969-9961(20)30226-6
doi: 10.1016/j.nbd.2020.104951
pii:
doi:

Substances chimiques

HTT protein, human 0
Huntingtin Protein 0
Green Fluorescent Proteins 147336-22-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104951

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no competing interest.

Auteurs

Alexander Maxan (A)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada.

Giacomo Sciacca (G)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada.

Melanie Alpaugh (M)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada.

Zhu Tao (Z)

Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.

Ludivine Breger (L)

Université de Bordeaux, Institut des maladies neurodégénératives, UMR 5293, CNRS UMR 5293, Bordeaux, France; Centre National de la Recherche Scientifique, Institut des maladies neurodégénératives, UMR 5293, 33076 Bordeaux, France.

Benjamin Dehay (B)

Université de Bordeaux, Institut des maladies neurodégénératives, UMR 5293, CNRS UMR 5293, Bordeaux, France; Centre National de la Recherche Scientifique, Institut des maladies neurodégénératives, UMR 5293, 33076 Bordeaux, France.

Zhang Ling (Z)

Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.

Qin Chuan (Q)

Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China. Electronic address: chuanqin@vip.sina.com.

Giulia Cisbani (G)

University of Toronto, Department of Nutritional Sciences, Toronto, ON M5S 1A8, Canada.

Maria Masnata (M)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada.

Shireen Salem (S)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada.

Steve Lacroix (S)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada; Département de Médicine Moléculaire, Université Laval, Québec, QC G1K 0A6, Canada.

Abid Oueslati (A)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada; Département de Médicine Moléculaire, Université Laval, Québec, QC G1K 0A6, Canada.

Erwan Bezard (E)

Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China; Université de Bordeaux, Institut des maladies neurodégénératives, UMR 5293, CNRS UMR 5293, Bordeaux, France; Centre National de la Recherche Scientifique, Institut des maladies neurodégénératives, UMR 5293, 33076 Bordeaux, France.

Francesca Cicchetti (F)

Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC G1V 4G2, Canada; Département de Psychiatrie & Neurosciences, Université Laval, Québec, QC G1K 0A6, Canada. Electronic address: francesca.cicchetti@crchudequebec.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH